News stories about Anika Therapeutics (NASDAQ:ANIK) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anika Therapeutics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.2647330114124 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of research analysts have commented on ANIK shares. Zacks Investment Research upgraded Anika Therapeutics from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Monday, August 6th. ValuEngine upgraded Anika Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 27th. First Analysis lowered Anika Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $45.00 to $34.00 in a research report on Wednesday, June 20th. BidaskClub lowered Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 29th. Finally, Barrington Research lowered Anika Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 20th. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $43.00.
NASDAQ:ANIK opened at $42.38 on Wednesday. Anika Therapeutics has a 12-month low of $28.54 and a 12-month high of $69.81. The firm has a market capitalization of $603.61 million, a PE ratio of 21.62, a P/E/G ratio of 2.67 and a beta of 2.04.
Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, July 25th. The biotechnology company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.39. Anika Therapeutics had a return on equity of 9.53% and a net margin of 16.94%. The business had revenue of $30.55 million for the quarter, compared to analyst estimates of $27.47 million. During the same period last year, the company earned $0.76 EPS. The firm’s revenue was down 8.7% on a year-over-year basis. research analysts anticipate that Anika Therapeutics will post 1.55 earnings per share for the current fiscal year.
About Anika Therapeutics
Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.
Further Reading: NASDAQ
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.